After hosting a call with a hepatologist treating 25 acute intermittent porphyria patients, Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Alnylam Pharmaceuticals with a $138 price target. The stock has been under pressure due to concerns about the Onpattro launch and competitor Vyndamax, Young tells investors in a research note. However, she notes the hepatologist was positive on Alnylam's givosiran and emphasized the high unmet need. Although diagnosis will be a headwind, givosiran will see "significant uptake" in the first year of its early 2020 launch, says the analyst. She believes Alnylam's current valuation likely discounts this opportunity.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).